Concepedia

Author

Vânia Hungria

São Germano Oncologia

Also Known As

Sosana Delimpasi, V. Hungria, Vania Hungria, Vânia Hungria

56

Publications

383

Citations

7

H-Index

8

Concepts

All Affiliations

São Germano OncologiaVrije Universiteit AmsterdamTel Aviv Sourasky Medical CenterTel Aviv UniversityUniversity Hospital Brno
VH

About

Vânia Hungria is an author at São Germano Oncologia specializing in rheumatoid arthritis, health sciences, and bone metabolism.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

63

2

Medicine

1

1

63

3

Orthopaedics

1

1

63

4

Clinical Trials

1

1

63

5

Bone Health

1

1

63

Vânia Hungria

×

6

Publications

333

Citations

6

H-Index

YearCitations

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Vânia Hungria, Paweł Robak, Marek Hus,

New England Journal of Medicine

2024

127

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Saad Z. Usmani, Thierry Façon, Vânia Hungria,

Nature Medicine

2025

74

Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid

Saroj Vadhan‐Raj, Roger von Moos, Lesley Fallowfield,

Annals of Oncology

2012

63

Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial

Meletios Α. Dimopoulos, Sundar Jagannath, Sung‐Soo Yoon,

Blood

2011

40

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špıčka,

Blood

2024

18

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Sonja Zweegman, Thierry Façon, Vânia Hungria,

Blood

2024

11

Page 1